Cargando…
SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
Introduction: Alemtuzumab, an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis is most commonly associated with Graves disease, but autoimmune hypothyroidism may also be seen. We present an unusual case where both were present in the same patient and prog...
Autores principales: | Rapier, Brandon, Gargasz, Frank, Zmeili, Omar Suheil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208363/ http://dx.doi.org/10.1210/jendso/bvaa046.400 |
Ejemplares similares
-
SAT-481 Pembrolizumab-Induced Thyroiditis with Negative Thyroid Peroxidase Antibody
por: Ragunanthan, Branavan, et al.
Publicado: (2020) -
SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020) -
SAT-581 Graves' Disease and Hashimoto's Thyroiditis: Two Ends of a Spectrum
por: Morselli, Lisa, et al.
Publicado: (2019) -
SAT-497 Conversion of Hashimoto’s Thyroiditis to Grave’s Disease: A Case Report
por: Wahedi, Tayba S, et al.
Publicado: (2020) -
ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)